OncoIndustry
Ivonescimab Expands Into First-Line Bladder Cancer – Summit Therapeutics
Summit Therapeutics

Ivonescimab Expands Into First-Line Bladder Cancer – Summit Therapeutics

Summit Therapeutics, Inc. , shared on LinkedIn:

“Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer.

HARMONi-GU1 Is First Global Registrational Clinical Trial of Ivonescimab in a Genitourinary (GU) Cancer, Adding to Global Phase III Ivonescimab Studies in NSCLC and CRC Clinical Trial Site Activations Globally Planned to Begin by Q4 2026.

Full Press Release.”

bladder cancer cancer clinical trials drug development First-Line Bladder Cancer Genitourinary Cancer Global Clinical Trial GU cancer HARMONi-GU1 ivonescimab OncoDaily Oncology Phase II trial Phase III trial Registrational Trial Summit Therapeutics urothelial carcinoma